NRG Oncology CC001 Neurocognitive Final Analysis: A Phase III Trial of Hippocampal Avoidance (HA) in Addition to Whole-Brain Radiotherapy (WBRT) Plus Memantine to Preserve Neurocognitive Function (NCF) in Patients With Brain Metastases (BM)
Article
Wefel, Jeffrey S, Pugh, Stephanie, Gondi, Vinai et al. (2019). NRG Oncology CC001 Neurocognitive Final Analysis: A Phase III Trial of Hippocampal Avoidance (HA) in Addition to Whole-Brain Radiotherapy (WBRT) Plus Memantine to Preserve Neurocognitive Function (NCF) in Patients With Brain Metastases (BM)
. NEUROSURGERY, 66(Supplement 1), 310-642. 10.1093/neuros/nyz310_642
Wefel, Jeffrey S, Pugh, Stephanie, Gondi, Vinai et al. (2019). NRG Oncology CC001 Neurocognitive Final Analysis: A Phase III Trial of Hippocampal Avoidance (HA) in Addition to Whole-Brain Radiotherapy (WBRT) Plus Memantine to Preserve Neurocognitive Function (NCF) in Patients With Brain Metastases (BM)
. NEUROSURGERY, 66(Supplement 1), 310-642. 10.1093/neuros/nyz310_642